Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Liraglutide Versus Placebo in Weight Loss Maintenance in Obese Subjects: SCALE - Maintenance

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Body Mass Index (BMI) of either 30 kg/m\^2 or more or BMI of less than 30 kg/m\^2 to 27 kg/m\^2 with presence of co-morbidities~* Stable body weight during the previous 3 months (less than 5 kg self-reported weight change)~* Previously undergone dietary weight loss and was not able to maintain reduced weight~Exclusion Criteria:~* Diagnosis of type 1 or type 2 diabetes~* Previous treatment with GLP-1 (glucagon-like peptide-1) receptor agonists (including liraglutide or exenatide), within the last 3 months~* Visit 1 thryoid stimulating hormone (TSH) outside of the range of 0.4-6.0 mIU/L~* History of chronic pancreatitis or idiopathic acute pancreatitis~* Obesity induced by other endocrinologic disorders (e.g., Cushing Syndrome)~* Current or history of treatment with medications that may cause significant weight gain for at least 3 months before this trial~* Current participation in an organized diet reduction program (or within the last 3 months)~* Currently using or have used within three months before this trial: pramlintide, sibutramine, orlistat, zonisamide, topiramate, phenteremine, or metformin~* Previous surgical treatment for obesity (excluding liposuction if performed more than one year before trial entry)~* History of major depressive disorder or a PHQ-9 (Patient Health Questionnaire-9) score of more than 15 within the last 2 years or history of other severe psychiatric disorders or diagnosis of an eating disorder~* Subjects with a lifetime history of a suicide attempt or history of any suicidal behavior within the past month before entry into the trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lira 3.0 mg (Type: EXPERIMENTAL): A 12-week run-in period where screened subjects were treated with a low calorie diet. Randomised subjects (those who lost more than or equal to 5% of screening body weight) were treated with liraglutide 3.0 mg, once daily, injected subcutaneously and instructed to follow a standard energy-restricted diet in the 56-week main trial period. Subjects discontinued treatment in the 12-week follow-up period. The starting dose of liraglutide was 0.6 mg, with weekly increments of 0.6 mg every 7 days until the target dose of 3.0 mg was reached
- Placebo (Type: PLACEBO_COMPARATOR): A 12-week run-in period where screened subjects were treated with a low calorie diet. Randomised subjects (those who lost more than or equal to 5% of screening body weight) were treated with liraglutide placebo, once daily, injected subcutaneously for 56 weeks and instructed to follow a standard energy-restricted diet in the 56-week main trial period. Subjects discontinued treatment in the 12-week follow-up period

Based on this trial design, predict the completion outcome and termination type (if applicable).